Stryker Corporation (NYSE:SYK) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Stryker Corporation (NYSE:SYK) have been given a consensus recommendation of “Moderate Buy” by the twenty-two brokerages that are currently covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $395.3333.

Several brokerages have weighed in on SYK. Evercore set a $355.00 target price on Stryker in a research note on Friday, May 1st. BTIG Research cut their target price on Stryker from $397.00 to $379.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. Jefferies Financial Group reaffirmed a “buy” rating and set a $465.00 target price on shares of Stryker in a research note on Wednesday, March 4th. Wells Fargo & Company cut their target price on Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. Finally, JPMorgan Chase & Co. cut their target price on Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st.

Stryker Trading Down 1.0%

NYSE:SYK opened at $305.82 on Friday. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. The business’s 50 day moving average is $316.75 and its two-hundred day moving average is $344.20. Stryker has a 52 week low of $281.00 and a 52 week high of $404.87. The company has a market cap of $117.24 billion, a PE ratio of 35.40, a P/E/G ratio of 1.95 and a beta of 0.78.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). The company had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period last year, the business posted $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, analysts predict that Stryker will post 14.98 EPS for the current year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be given a dividend of $0.88 per share. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.2%. Stryker’s dividend payout ratio (DPR) is 40.74%.

Insider Activity

In other news, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the transaction, the director directly owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. This trade represents a 13.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the transaction, the vice president owned 10,582 shares in the company, valued at approximately $3,247,298.34. This trade represents a 30.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 323,264 shares of company stock worth $100,659,489. 4.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. grew its holdings in shares of Stryker by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock valued at $11,917,396,000 after buying an additional 133,892 shares in the last quarter. State Street Corp boosted its position in Stryker by 2.1% during the fourth quarter. State Street Corp now owns 15,254,407 shares of the medical technology company’s stock valued at $5,374,731,000 after purchasing an additional 311,507 shares during the last quarter. Geode Capital Management LLC boosted its position in Stryker by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company’s stock valued at $2,636,238,000 after purchasing an additional 69,851 shares during the last quarter. Wellington Management Group LLP boosted its position in Stryker by 22.6% during the fourth quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock valued at $2,282,192,000 after purchasing an additional 1,198,665 shares during the last quarter. Finally, Alliancebernstein L.P. boosted its position in Stryker by 13.3% during the third quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock valued at $2,342,987,000 after purchasing an additional 741,542 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.